EMD-7108

Single-particle
26.0 Å
EMD-7108 Deposition: 07/11/2017
Map released: 06/12/2017
Last modified: 06/12/2017
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links

EMD-7108

HIV-1 Envelope Glycoprotein clone PC64M18c043 SOSIP.664

EMD-7108

Single-particle
26.0 Å
EMD-7108 Deposition: 07/11/2017
Map released: 06/12/2017
Last modified: 06/12/2017
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links
Sample Organism: Human immunodeficiency virus 1, Homo sapiens
Sample: HIV-1 Envelope Glycoprotein clone PC64M18c043 SOSIP.664 in complex with PGV04 Fab

Deposition Authors: Berndsen ZT, Rantalainen K, Ward AB
HIV Envelope Glycoform Heterogeneity and Localized Diversity Govern the Initiation and Maturation of a V2 Apex Broadly Neutralizing Antibody Lineage.
PUBMED: 29166592
DOI: doi:10.1016/j.immuni.2017.11.002
ISSN: 1097-4180
ASTM: IUNIEH
Abstract:
Understanding how broadly neutralizing antibodies (bnAbs) to HIV envelope (Env) develop during natural infection can help guide the rational design of an HIV vaccine. Here, we described a bnAb lineage targeting the Env V2 apex and the Ab-Env co-evolution that led to development of neutralization breadth. The lineage Abs bore an anionic heavy chain complementarity-determining region 3 (CDRH3) of 25 amino acids, among the shortest known for this class of Abs, and achieved breadth with only 10% nucleotide somatic hypermutation and no insertions or deletions. The data suggested a role for Env glycoform heterogeneity in the activation of the lineage germline B cell. Finally, we showed that localized diversity at key V2 epitope residues drove bnAb maturation toward breadth, mirroring the Env evolution pattern described for another donor who developed V2-apex targeting bnAbs. Overall, these findings suggest potential strategies for vaccine approaches based on germline-targeting and serial immunogen design.